RECRUITING

Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes have similar survival rates. This contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.

Official Title

Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Quick Facts

Study Start:2020-01-01
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04078230

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients \>18 years of age and ≤80 years of age;
  2. * Preoperative imaging and laboratory examination for intrahepatic cholangiocarcinoma, intraoperative frozen and postoperative pathology confirmed as intrahepatic cholangiocarcinoma; preoperative imaging assessment is resectable;
  3. * No obvious lymph node metastasis in preoperative imaging; or negative intraoperative lymph node biopsy
  4. * Liver function Child-Turcotte-Pugh score A-B grade;
  5. * Residual liver volume \>30%; can tolerate radical hepatectomy
  6. * The patient has autonomy, understands and voluntarily signs the written informed consent and is able to complete the follow-up plan;
  7. * Sign the written informed consent form prior to the test screening.
  1. * The patient has obvious heart, lung, brain and kidney dysfunction that affects the treatment of intrahepatic cholangiocarcinoma;
  2. * The patient has a history of other malignant tumors;
  3. * Liver function Child-Turcotte-Pugh score C;
  4. * The investigator determined that it was not suitable for the study.

Contacts and Locations

Study Contact

Jiang-Tao LI, PHD;MD
CONTACT
86-15906686716
zjulijiangtao@163.com

Study Locations (Sites)

The Johns Hopkins Hospital
Baltimore, Maryland, 10017
United States

Collaborators and Investigators

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-01-01
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2020-01-01
Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Intrahepatic Cholangiocarcinoma